Frontlight ResearchEarly access
WithdrawnPhase 3
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Key facts
- Who runs it
- Sagimet Biosciences Inc.
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- Mar 2025
- Expected to end
- Dec 2030
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Denifanstat
- Placebo
- Record updated
- 15 May 2025
- Why it stopped
- Business decision
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Willing and able to participate in the study and provide written informed consent
- Adults between 18 and 75 years of age
- Body mass index (BMI) ≥23 kg/m\^2 for Asian patients and ≥25 kg/m\^2 for patients of other races
- Presence of metabolic risk factor(s), as follows:; T2DM; OR; 2 out of 4 of the following:; BMI ≥30 kg/m\^2; Hypertension, or on active antihypertensive treatment; Elevated fasting serum TGs or on active treatment for hypertriglyceridemia; Reduced fasting serum HDL-c or on active treatment for dyslipidemia
- For patients with T2DM:; HbA1c ≤9.5%; Metformin, insulin, dipeptidyl peptidase-4 inhibitors (DPP4-Is), sodium-glucose transport protein-2 inhibitors (SGLT2-Is), and alpha-glucosidase inhibitors (α-GIs): stable dose for at least 12 weeks prior to qualifying liver biopsy and screening; Sulfonylureas (SUs) and glinides: stable dose with no history of relevant hypoglycemia for at least 12 weeks prior to qualifying liver biopsy and screening; GLP-1 RA: stable dose for at least 18 weeks prior to start of screening
- Noncirrhotic, biopsy-proven MASH with:; A fibrosis stage of F2 or F3; NAS ≥4 with at least a score of 1 in each of the following NAS components:; Steatosis (scored 0 to 3); Hepatocyte ballooning (scored 0 to 2); Lobular inflammation (scored 0 to 3)
- A qualifying historical liver biopsy within 6 months before the screening visit. Historical biopsy results will be confirmed by central reading; If there is no available historical liver biopsy within this time period, a liver biopsy must be performed during the screening period. Patients should be deemed likely to have MASH F2/F3 fibrosis prior to proceeding to a liver biopsy, as indicated by the following:; FibroScan; Liver stiffness measurement (LSM) ≥8.5 kPa; Controlled attenuation parameter (CAP) ≥280 dB/m; Aspartate aminotransferase (AST) >20 U/L
- Stable ALT and AST levels
Who cannot take part
- Previous intake of an approved MASH medication
- History of excessive alcohol intake for a period of more than 3 consecutive months within 1 year prior to screening
- Prior or planned bariatric surgery
- Gain or loss of >5% of body weight in the 3 months or >10% of body weight in the 6 months prior to screening, qualifying liver biopsy, and the baseline visit (V1)
- Any of the following within 6 months prior to the baseline visit (V1):; Myocardial infarction; CABG/PTCA; Unstable angina; Transient ischemic attack, stroke, or cerebrovascular disease
- Malignancy with a complete remission date within 5 years prior to the baseline visit (V1)
- Previous intake of an approved MASH medication, unless there is at least a 6-month wash-out period between the last date of intake of the approved MASH medication and date of screening
- Use of a nonpermitted concomitant medication within 30 days or 5 half-lives prior to the qualifying liver biopsy and screening
- Evidence of another form of active liver disease
- Positive serologic evidence of current infectious liver disease
- Planned or history of liver transplantation
- Unstable or undiagnosed arrhythmias
- Any current or history of hepatocellular carcinoma
- Diabetes other than T2DM
- Any other known serious disease or other disease which in the Investigator's opinion would exclude the patient from participating in the study
- Exclusionary laboratory values:; ALT and/or AST >5 × ULN; ALP ≥2 × ULN; Total serum bilirubin concentration >1.3 mg/dL; Serum albumin concentration <3.5 g/dL; INR >1.3 except for patients receiving anticoagulant treatment; Platelet count <140,000/μL; Fasting TG level ≥500 mg/dL; eGFR <45 mL/min/1.73 m\^2
- Presence of cirrhosis on liver histology according to the assessment of the central reader
- Current or historical clinically evident hepatic decompensation
- MELD score ≥12
- Uncontrolled high BP
- Uncontrolled hypothyroidism
About the trial
What the trial wants to find out
A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression without the worsening of steatohepatitis.
The 3 groups in the trial
- Denifanstat 50 mgTreatment being tested
Denifanstat tablet, orally, once daily
Treatment: Denifanstat
- Denifanstat 25 mgTreatment being tested
Denifanstat tablet, orally, once daily
Treatment: Denifanstat
- PlaceboPlacebo, for comparison
Placebo tablet, orally, once daily
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Denifanstat in Patients With Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis (MASH) and F2/F3 Fibrosis (FASCINATE-3)
- Publications
- Record updated
- 15 May 2025